JP2021518372A5 - - Google Patents

Info

Publication number
JP2021518372A5
JP2021518372A5 JP2020550071A JP2020550071A JP2021518372A5 JP 2021518372 A5 JP2021518372 A5 JP 2021518372A5 JP 2020550071 A JP2020550071 A JP 2020550071A JP 2020550071 A JP2020550071 A JP 2020550071A JP 2021518372 A5 JP2021518372 A5 JP 2021518372A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
pharmaceutical composition
composition according
i2fa
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020550071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023463 external-priority patent/WO2019183417A1/en
Publication of JP2021518372A publication Critical patent/JP2021518372A/ja
Publication of JP2021518372A5 publication Critical patent/JP2021518372A5/ja
Pending legal-status Critical Current

Links

JP2020550071A 2018-03-22 2019-03-21 修飾オリゴヌクレオチド及び使用方法 Pending JP2021518372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646901P 2018-03-22 2018-03-22
US62/646,901 2018-03-22
PCT/US2019/023463 WO2019183417A1 (en) 2018-03-22 2019-03-21 Modified oligonucleotides and methods of use

Publications (2)

Publication Number Publication Date
JP2021518372A JP2021518372A (ja) 2021-08-02
JP2021518372A5 true JP2021518372A5 (cg-RX-API-DMAC7.html) 2022-03-25

Family

ID=66223809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550071A Pending JP2021518372A (ja) 2018-03-22 2019-03-21 修飾オリゴヌクレオチド及び使用方法

Country Status (7)

Country Link
US (1) US20210015884A1 (cg-RX-API-DMAC7.html)
EP (1) EP3768840A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021518372A (cg-RX-API-DMAC7.html)
CN (1) CN112166191A (cg-RX-API-DMAC7.html)
CA (1) CA3094508A1 (cg-RX-API-DMAC7.html)
MA (1) MA52132A (cg-RX-API-DMAC7.html)
WO (1) WO2019183417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230340608A1 (en) * 2020-07-17 2023-10-26 European Molecular Biology Laboratory Prognostic biomarkers for cancer
CN116555325A (zh) * 2023-04-11 2023-08-08 内蒙古农业大学 本氏烟m6A甲基化酶基因在抗病毒中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017075451A1 (en) * 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
CN107349217B (zh) * 2017-07-21 2020-06-09 深圳大学 一种基于mettl3的小干扰rna及其药物和应用

Similar Documents

Publication Publication Date Title
JP2018126141A5 (cg-RX-API-DMAC7.html)
JP2019088329A5 (cg-RX-API-DMAC7.html)
JP2021512629A5 (cg-RX-API-DMAC7.html)
JP2020522244A5 (cg-RX-API-DMAC7.html)
JP2006515277A5 (cg-RX-API-DMAC7.html)
HRP20241138T1 (hr) Oligonukleotidi za induciranje ekspresije očinskog ube3a
JP2019068829A5 (cg-RX-API-DMAC7.html)
JP2016501513A5 (cg-RX-API-DMAC7.html)
JP2018150344A5 (cg-RX-API-DMAC7.html)
IL317818A (en) Oligonucleotides to reduce PD-L1 expression
JP2017513469A5 (cg-RX-API-DMAC7.html)
JP2016502858A5 (cg-RX-API-DMAC7.html)
WO2009109665A4 (en) Pharmaceutical compositions for treatment of microrna related diseases
JP2003520811A5 (cg-RX-API-DMAC7.html)
JP2014511686A5 (cg-RX-API-DMAC7.html)
JP2017070307A5 (cg-RX-API-DMAC7.html)
JP2016523548A5 (cg-RX-API-DMAC7.html)
JP2009511034A5 (cg-RX-API-DMAC7.html)
CA2520541A1 (en) Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field
JP2008523157A5 (cg-RX-API-DMAC7.html)
JP2009508527A5 (cg-RX-API-DMAC7.html)
JP2022501024A5 (cg-RX-API-DMAC7.html)
JP2021500016A5 (cg-RX-API-DMAC7.html)
JP2021505129A5 (cg-RX-API-DMAC7.html)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ